PEPTIDE
European patent · EP3030259 · In force
Register entry
- Publication number
- EP3030259
- Application number
- EP14772444
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Aug 6, 2014
- Published
- Jun 15, 2016
- Granted
- Dec 27, 2017
- Protection ends at the latest
- Aug 5, 2034
- Next annual fee due
- Aug 31, 2027
- IPC classes
- A61K 39/00 (2006.01)C07K 14/72 (2006.01)C07K 7/08 (2006.01)
- Priority
- GB 201314052 06.08.2013
- PCT application
- PCT/IB2014/063739 06.08.2014
- PCT publication
- WO2015/019302 12.02.2015
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Sep 1, 2026
Next annual fee due on
- Next annual fee due on
- 31.08.2026 → 31.08.2027
Published in Swissreg on 01.09.2026
- Sep 1, 2025
Next annual fee due on
- Next annual fee due on
- 31.08.2025 → 31.08.2026
Published in Swissreg on 01.09.2025
- Jan 13, 2025
Next annual fee due on
- Next annual fee due on
- 31.08.2024 → 31.08.2025
Published in Swissreg on 13.01.2025
- Nov 20, 2023
Transferred
- Owner
- Apitope International NV, Campus Diepenbeek, Agoralaan, 3590 Diepenbeek, Belgium → Worg Pharmaceuticals (Zhejiang) Co., Ltd., Room 215, Building 2, 198 Bandaozhonglu Road, Dipu Street, Anji County, Huzhou, Zhejiang, China
Published in Swissreg on 20.11.2023
- Sep 1, 2023
Change
Published in Swissreg on 01.09.2023
- Sep 1, 2022
Change
Published in Swissreg on 01.09.2022
- Dec 27, 2017
Granted
Published in Swissreg on 27.12.2017
Parties
Inventor
WRAITH, David
Bristol BS8 1TD, GB
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.